Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Clinical trial NCT03562832 · COMPLETED
Trial details
- NCT number
- NCT03562832
- Sponsor
- Allarity Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-20
- Primary completion
- 2024-04-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.